Supplementary Online Content
|
|
- August Cook
- 5 years ago
- Views:
Transcription
1 Supplementary Online Content Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of Noninsulin Antidiabetic Drugs Added to Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes. JAMA. 2010;303(14): etable. e Characteristics of Randomized Controlled Trials Evaluating Noninsulin Antidiabetic Drugs in Addition to in Type 2 Diabetes Mellitus efigure 1. Overall Network Diagram of Randomized Controlled Trials Evaluating Noninsulin Antidiabetic Drugs in Addition to in Type 2 Diabetes Mellitus efigure 2. Network Diagram of Randomized Controlled Trials Evaluating Change From e in A1c (%) With Noninsulin Antidiabetic Drugs in Addition to in Type 2 Diabetes Mellitus efigure 3. Network Diagram of Randomized Controlled Trials Evaluating A1c Goal Achieved (RR) With Noninsulin Antidiabetic Drugs in Addition to in Type 2 Diabetes Mellitus efigure 4. Network Diagram of Randomized Controlled Trials Evaluating Change From e in Body Weight (kg) With Noninsulin Antidiabetic Drugs in Addition to in Type 2 Diabetes Mellitus efigure 5. Network Diagram of Randomized Controlled Trials Evaluating Overall Hypoglycemia (RR) With Noninsulin Antidiabetic Drugs in Addition to in Type 2 Diabetes Mellitus efigure 6. Results of Mixed Treatment Comparison Meta-analysis Presented as Forest Plots This supplementary material has been provided by the authors to give readers additional information about their work.
2 etable. e Characteristics of Randomized Controlled Trials Evaluating Noninsulin Antidiabetic Drugs in Addition to in Type 2 Diabetes Mellitus Study Name, Year N DeFronzo, N=370 Ferrannini, N=2789 Goodman, N=247 Nauck, 2009a 13 N=314 Nauck, 2009b 14 N = 608 Bolli, ,16 N=576 Jadad Score* Followup () Inclusion Criteria 2,2,1 24 A1c: 7-10% Dose: Duration: 2 BMI: 40 1,2,1 52 A1c: % Dose: 1500 Duration: >4 BMI: ,1,1 24 A1c: % Dose: 1500 Duration: 12 BMI: ,1,1 26 A1c: 7-10% Dose: 1500 Duration: 12 BMI: ,2,1 26 A1c: 7-11% (prestudy OAD monotherapy 3 ) or 7-10% (prestudy combination OAD 3 ) Dose: 3 week forced titration, final dose 2000 BID Duration: 3 following forced titration (6 total) BMI: 40 1,0,1 52 A1c: % Dose: 1500 Intervention s Evaluated Saxagliptin 5 Population Sample Characteristics size (Age, Males) 191 Age (yrs): 54.7 ± 9.6 Males (%): 53.9 Placebo 179 Age (yrs): 54.8 ± 10.2 Males (%): 53.6 Vildagliptin 100 Glimepiride up to 6 Vildagliptin 100 (in the morning) 1396 Age (yrs): 57.5 ± 9.06 Males (%): Age (yrs): 57.5±9.28 Males (%): Age (yrs): 54.7 ± 10.3 Males (%): 52.8 Placebo 122 Age (yrs): 54.5 ± 9.7 Males (%): 67.2 Alogliptin Age (yrs): 54 ± 11 Males (%): 54.3 Placebo 104 Age (yrs): 56 ± 11 Males (%): 48 Liraglutide 1.8 Glimepiride Age (yrs): 57 ± 9 Males (%): Age (yrs): 57 ±9 Males (%): 57 Placebo 122 Age (yrs): 56 ± 9 Males (%): 60 Vildagliptin Age (yrs): 56.3 ± 9.3 Males (%): 61.7 e A1c (%) 8.1 ± ± 7.31 ± ± 0.65 e Fasting Plasma Glucose (l) e Weight (kg) 180 ± ± ± ± ± ± ± ± ± 7.9 ± ± 50.4 e BMI ( ) 31.2 ± ± ± ± 5.25 NR 31.7 ± 4.6 NR 31.7 ± 4.3 Duration of DM (years) 6.4 ± 4.7 NR 6.7 ± 5.6 NR 5.71 ± ± 5.03 Metformi n Dose (mg) ± ± 408 NR 1889 ± NR ± ± 45 NR 32 ± 5 6 ± ± ± 180 ± 50.4 NR 32 ± 6 6 ± ± ± 41.4 NR 3 ± ± 46.8 NR 31.2 ± ± 41.4 NR 31.6 ± ± ± ± ± 5 NR 8 ± 5 NR 8 ± 6 NR 6.4 ± ± 454
3 Study Name, Year N Hamann, N=595 Khanolkar, N=50 Raz, N=190 Scott, N=273 Ahrén, ,22 N=71 Bosi, N=273 Jadad Score* Followup () Inclusion Criteria Duration: at least 4 week run-in BMI: ,1,1 52 A1c: 7-10% Dose: >850 Duration: 8 BMI: 25 1,1,1 24 A1c: >6.5% Dose: 2000 Duration: 4 BMI: NR 2,1,1 30 A1c: 8-11% Dose: >1500 Duration: 6 BMI: ,1,1 18 A1c: 7-11% Dose: 1500 Duration: 10 1,1,1 52 A1c: 7-9.5% Dose: Duration: 3 BMI: ,1,1 24 A1c: % Dose: 1500 Duration: 3 BMI: Intervention s Evaluated Pioglitazone 30 Rosiglitazone 4 Glibenclimide 5 or Gliclazide 80 Rosiglitazone 4 Gliclazide 80 Sitagliptin 100 Population Sample Characteristics size (Age, Males) 281 Age (yrs): 57 ± 9.7 Males (%): Age (yrs): 58.5 ± 9.6 Males (%): Age (yrs): 59.3 ± 9.2 Males (%): Age (yrs): 59 ± Males (%): Age (yrs): 56 ± Males (%): Age (yrs): 53.6 ± 9.5 Males (%): 51 Placebo 94 Age (yrs): 56.1 ± 9.5 Males (%): 41.5 Sitagliptin 100 Rosiglitazone 8 94 Age (yrs): 55.2 ± 9.8 Males (%): Age (yrs): 54.8 ± 10.5 Males (%): 63 BMI: NR Placebo 92 Age (yrs): 55.3 ± 9.3 Males (%): 59 Vildagliptin Age (yrs): 58.4 ± 9.2 Males (%): 61.9 Placebo 29 Age (yrs): 54.3 ± 12.2 Males (%): 75.9 Vildagliptin Age (yrs): 53.9 ± 9.5 Males (%): 61.5 Placebo 130 Age (yrs): 54.5 ± 10.3 Males (%): 53.1 e A1c (%) e Fasting Plasma Glucose (l) e Weight (kg) 198 ± ± ± 189 ± ± ± ± ± ± ± 9.1 ± ± 16.6 e BMI ( ) 32.1 ± 5.1 Duration of DM (years) Metformi n Dose (mg) 6.4 ± ± ± ± 5.4 NR 32.2 ± 4.9 NR NR ± 8.83 NR NR ± ± ± ± ± ± 7.6 ± ± ± 81.5 ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± 5.5 NR 29.6 ± 3.7 NR 29.9 ± 3.6 NR 32.9 ± 5.0 NR 33.2 ± ± 5.6 NR NR NR NR NR 6.5 NR 7.3 ± 5.3 NR 4.9 ± 3.5 NR 4.6 ± 4.0 NR 30 ± ± 3.7 NR 5.8 ± 4.2 NR 4.6 ± 3.6 NR 5.8 ± ± ± ± 320
4 Study Name, Year N Nauck, N=1172 Charbonnel, N=701 Garber, N=318 Ristic, ,28 N=213 DeFronzo, N=226 Feinglos, N=122 Jadad Score* Followup () Inclusion Criteria 1,1,1 52 A1c: % Dose: 1500 Duration: 2 BMI: NR 1,1,1 24 A1c: 7-10% Dose:1500 Duration: up to 19 BMI: NR 1,2,1 24 A1c: 7-12% Dose: 1500 Duration: 2 BMI: ,2,1 52 A1c: 6.8-9% Dose:1000 Duration: >2 BMI: ,2,1 30 A1c: % Dose: 1500 Duration: 3 BMI: ,1,1 16 A1c: % Dose: 1000 Duration: 3 BMI: Intervention s Evaluated Sitagliptin 100 Glipizide 5 (titrated up to a maximum of 20) Sitagliptin 100 Population Sample Characteristics size (Age, Males) 588 Age (yrs): 56.8 ± 9.3 Males (%): Age (yrs): 56.6 ± 61.3 Males (%): Age (yrs): 54.4 ± 10.4 Males (%): 55.8 Placebo 237 Age (yrs): 54.7 ± 9.7 Males (%): 59.5 Glibenclamide up to 10 Rosiglitazone up to 8 Nateglinide 180,360 or 540 Gliclazide 80,160 or 240 Exenatide 20 mcg/d 160 Age (yrs): 56 Males (%): Age (yrs): 56 Males (%): Age (yrs): 61.9 ± 1 Males (%): Age (yrs): 61.5 ± 10.2 Males (%): Age (yrs): 52 ± 11 Males (%): 60.2 Placebo 113 Age (yrs): 54 ± 9 Males (%): 59.3 Glipizide GITS 2.5 ay 61 Age (yrs): 57.7 ± 10.7 Males (%): 46 Placebo 61 Age (yrs): 58.8 ± 10 Males (%): 41 e A1c (%) 7.7 ± 7.6 ± 8.0 ± ± ± ± ± ± 8.2 ± 7.45 ± ± 0.78 e Fasting Plasma Glucose (l) ± ± ± ± 41.4 e Weight (kg) 89.5 ± ± ± ± 17.5 e BMI ( ) 31.2 ± ± ± ± 4.9 Duration of DM (years) 6.5 ± 6.1 NR 6.2 ± 5.4 NR 6.0 ± 5.0 NR 6.6 ± 5.5 NR 191 ± ± ± 5 5 ± 4 NR 188 ± ± ± 5 6 ± 5 NR ± ± ± ± ± ± ± ± ± ± 18.4 NR 28.6 ± 3.5 NR 30.0 ± ± ± 5.40 Metformi n Dose (mg) ± ± 4.7 NR 34 ± ± 6.1 NR 31.7 ± ±
5 Study Name, Year N Matthews, N=630 Jadad Score* Followup () Inclusion Criteria 1,2,1 52 A1c: % Dose: 50% of the maximum recommended dose or at the maximum tolerated dose Duration: 3 BMI: NR 1,1,1 26 A1c: NR Dose: 2500 Duration: initial 3-6 week titration phase prior to randomization BMI: NR 2,2,1 24 A1c: % Dose: 1500 Duration: 3 BMI: ,2,1 20 A1c: NR Dose: 2550 Duration: 1 month BMI: for females; for males 2,2,0 32 A1c: % Dose: Duration: 3 BMI: ,1,1 26 A1c: NR Dose: 2500 Duration: NR BMI: Gómez- Perez, N=70 Marre, N=312 Charpentier, N = 222 Van Gaal, N=152 Fonseca, N=223 Intervention s Evaluated Pioglitazone up to 45 Gliclazide up to 320 Rosiglitazone 8 Population Sample Characteristics size (Age, Males) 317 Age (yrs): 56 ± 9.2 Males (%): Age (yrs): 57 ± 9.0 Males (%): Age (yrs): 54.2 ± 9.3 Males (%): 19.4 Placebo 34 Age (yrs): 53.4 ± 7.5 Males (%): 29.4 Nateglinide Age (yrs): 57.3 ± 10.5 Males (%): 61.3 Placebo 152 Age (yrs): 56.4 ± 10.3 Males (%): 55.3 Glimepiride 1 (titrated up to 2, 4 or 6 ) 147 Age (yrs): 56.8 Males (%): 59 Placebo 75 Age (yrs): 56.7 Males (%): 60 Miglitol up to Age (yrs): 57.9 ± 10 Males (%): 42 Placebo 75 Age (yrs): 57.9 ± 8.5 Males (%): 49 Rosiglitazone 8 ay 110 Age (yrs): 58.3 ± 8.8 Males (%): 68.2 Placebo 113 Age (yrs): 58.8 ± 9.2 Males (%): 74.3 e A1c (%) 8.71 ± 8.53 ± 0.89 e Fasting Plasma Glucose (l) ± ± 46.8 e Weight (kg) 91.8 ± ± 17.4 e BMI ( ) 32.6 ± ± 5.8 NR NR NR 27.6 ± 3.2 Duration of DM (years) 5.8 ± ± ±7.0 NR NR NR NR 28.5± ±5.6 NR ± ± ± 6.8 ± ± 8.9 ± ± ± ± ± ± ± ± ± ± ± ± ± 5.5 NR 6.5 ± 6.5 NR NR NR Metformi n Dose (mg) NR 30 ± 4.0 NR 1807 ± 371 NR 29.7 ± 3.9 NR 29.8 ± 3.9 NR 30.3 ± 4.4 NR 1812 ± ± 6.3 NR 7.3 ± 5.7 NR
6 Study Name, Year N Halimi, N=129 Moses, ,39 N = 54 Rosenstock, N = 148 Jadad Score* Followup () Inclusion Criteria 1,1,1 24 A1c: 7-11% Dose: 1700 or 2550 Duration: 2 BMI: ,1,1 12 A1c: > 7.1% Dose: Duration: > 6 BMI: 21 1,1,0 24 A1c: 7-10% Dose: 2000 or 2500 Duration:NR BMI: NR Intervention s Evaluated Acarbose up to 300 Population Sample Characteristics size (Age, Males) 59 Age (yrs): 56 ± 9.2 Males (%): 47 Placebo 70 Age (yrs): 55 ± 10 Males (%): 63 Repaglinide up to Age (yrs): 57.2 ± 8.3 Males (%): 67 Placebo 27 Age (yrs): 57.8 ± 9.5 Males (%): 63 Acarbose up to Age (yrs): 57.2 Males (%): 61 Placebo 74 Age (yrs): 55.9 Males (%): 49 e A1c (%) 8.6 ± 8.5 ± 8.3 ± 8.6 ± e Fasting Plasma Glucose (l) e Weight (kg) e BMI ( ) 189 ± 55.8 NR 30.1 ± ± 48.6 NR 29.7 ± ± 4 NR 33.2 ± ± NR 31.8 ± 6.0 Duration of DM (years) 9.5 ± 7.4 NR 9 ± 7.5 NR Metformi n Dose (mg) 5.9 ± ± ± ± NR NR Values reported as mean±sd when available. * Jadad score presented as subscores for randomization (up to 2 points), double-blinding (up to 2 points), description of withdrawals (up to 1 point). These individual components can be summed to achieve the total Jadad score. Abbreviations: A1c=glycosylated hemoglobin; BMI=body mass index; NR=not reported; yrs=years
7 Placebo 3 studies Reference 12,29,32 1 study Reference 25,26 2 studies Reference 31,36,37 4 studies Reference 13,16,24,28 3 studies Reference 18,30,34 8 studies Reference 8,10,11,17-21,23 3 studies Reference 33,35,38 1 study Reference 12 2 studies Reference 12,27 2 studies Reference 9,22 2 studies Reference 14,15,18 efigure 1. Overall Network Diagram of Randomized Controlled Trials Evaluating Noninsulin Antidiabetic Drugs in Addition to in Type 2 Diabetes Mellitus All agents are in combination with metformin. Lines represent the presence of direct comparison trial(s). Abbreviations: AGI=alpha-glucosidase inhibitor; DPP-4=dipeptidyl peptidase-4; GLP- 1=glucagon-like peptide-1; SU=sulfonylurea; TZD=thiazolidinediones
8 Placebo N=4; (-0.32, 0.11) (-0.31, 0.13) N=1; 0.00 (-0.28, 0.28) (-0.77, 0.12) N=3; (-5, -0.43) (-7, -0.62) N=3; -0 (-1.62, -0.38) (-8, -0.66) N=2; -9 (-9, -0.78) -7 (-1.30, -0.65) (-0.80, 0.36) N=1; (-0.42, 0.16) (-0.49, 0.25) (-0.56, 0.14) N=2; (-1.24, -0.18) (-7, -0.36) (-0.76, 0.14) N=2; (-0.13, -0.01) (-0.22, 0.22) N=2; (-1, -0.19) (-3, -0.26) (-0.63, 0.34) N=8; (-4, -0.63) (-3, -0.64) (-0.45, 0.20) (-0.51, 0.48) (-0.65, 0.42) N=2; (-0.16, 0.10) (-0.44, 0.16) (-0.55, 0.26) (-0.84, 0.17) (-0.52, 0.17) efigure 2. Network Diagram of Randomized Controlled Trials Evaluating Change From e in A1c (%) With Noninsulin Antidiabetic Drugs in Addition to in Type 2 Diabetes Mellitus All agents are in combination with metformin. Solid lines represent the presence of direct evidence along with indirect evidence. Dotted lines represent the presence of indirect evidence only. Traditional pairwise meta-analysis results are reported as the top line in the format n=number of studies; change in A1c (95%CI). Mixed-treatment comparison meta-analysis results, which combine both direct and indirect evidence are reported in the format change in A1c (95%CrI). Arrows represent the favored drug in the mixed-treatment comparison metaanalysis and results reported are referent to the arrow origin. Abbreviations: AGI=alpha-glucosidase inhibitor; DPP-4=dipeptidyl peptidase-4; GLP- 1=glucagon-like peptide-1; SU=sulfonylurea; TZD=thiazolidinediones
9 Placebo N=1; 1.27 (3, 1.58) 0 (0.69, 1.47) N=1; 7 (4, 1.46) 1.29 (0.79, 2.45) N=1; 3.38 (2.02, 5.83) 2.49 (1.95, 3.32) N=1; 1.69 (1.24, 2.33) 2.71 (1.74, 3.80) N=1; 3.96 (2.37, 6.79) 3.20 (2.01, 6.24) N=1; 1.33 (9, 1.82) 0 (0.68, 1.64) 1.21 (0.60, 1.92) 1.42 (0.73, 2.92) N=2; 1 (3, 0) 1 (0.79, 1.29) N=1; 3.20 (1.47, 7.58) 2.25 (1.48, 3.90) N=6; 2.44 (1.78, 3.33) 2.51 (2.04, 3.22) 2 (0.65, 1.72) 7 (0.71, 2.69) N=1; 5 (0, 1.47) 9 (0.67, 1.47) 1.27 (0.77, 2.45) efigure 3. Network Diagram of Randomized Controlled Trials Evaluating A1c Goal Achieved (RR) With Noninsulin Antidiabetic Drugs in Addition to in Type 2 Diabetes Mellitus All agents are in combination with metformin. Solid lines represent the presence of direct evidence along with indirect evidence. Dotted lines represent the presence of indirect evidence only. Traditional pairwise meta-analysis results are reported as the top line in the format n=number of studies; relative risk (95%CI). Mixed-treatment comparison meta-analysis results, which combine both direct and indirect evidence are reported in the format relative risk (95%CrI). Arrows represent the favored drug in the mixed-treatment comparison metaanalysis and results reported are referent to the arrow origin. Thus, results may not correspond to numerical results reported elsewhere. Results referent to the second agent in a comparison equal 1/RR. Abbreviations: AGI=alpha-glucosidase inhibitor; DPP-4=dipeptidyl peptidase-4; GLP- 1=glucagon-like peptide-1; SU=sulfonylurea; TZD=thiazolidinediones
10 Placebo N=2; 0.20 (-2.35, 2.74) (-5, 4) (-5.41, -2.75) N=2; (-3.12, -0.86) (-2.96, -5) N=1; (-2.90, -1.70) (-3.17, -8) N=2; (-2.90, -0.62) (-3.11, -0.48) (-5.98, -0.48) (-1.75, 1.46) (-2.00, 1.60) N=2; (-2.80, -1.42) (-3.02, -1.32) N=2; -1 (-1.46, -0.35) (-3.28, -0.46) (-5.63, -1.70) N=1; (-2.83, -0.77) (-3.79, 0.21) (-5.89, -1.66) N=4; (-0.47, 0.30) (-4, 0.63) (-3.65, -0.40) (-6.11, -1.20) (-5.41, -9) N=2; (-2.60, -1.63) (-2.91, -0.46) (-3.79, 0.54) (-2.42, 2.46) (-3.18, -0.07) efigure 4. Network Diagram of Randomized Controlled Trials Evaluating Change From e in Body Weight (kg) With Noninsulin Antidiabetic Drugs in Addition to in Type 2 Diabetes Mellitus All agents are in combination with metformin. Solid lines represent the presence of direct evidence along with indirect evidence. Dotted lines represent the presence of indirect evidence only. Traditional pairwise meta-analysis results are reported as the top line in the format n=number of studies; change in weight (95%CI). Mixed-treatment comparison meta-analysis results, which combine both direct and indirect evidence are reported in the format change in weight (95%CrI). Arrows represent the favored drug in the mixed-treatment comparison meta-analysis and results reported are referent to the arrow origin. Abbreviations: AGI=alpha-glucosidase inhibitor; DPP-4=dipeptidyl peptidase-4; GLP- 1=glucagon-like peptide-1; SU=sulfonylurea; TZD=thiazolidinediones
11 Placebo N=3; 0.11 (0.04, 0.29) 0.12 (0.04, 0.30) N=1; 0.17 (0.08, 0.36) 0.20 (0.04, 7) N=3; 0.38 (0.11, 1.32) 0.22 (0.09, 0.47 N=2; 2.04 (0.50, 8.23) 0.56 (0.19, 1.69) N=2; 4 (0.42, 2.12) 0.89 (0.22, 3.96) 0.73 (0.01, 19.50) N=1; 3 (0.51, 1.69) 0.60 (0.12, 2.22) 0.07 (0.01, 0.33) N=2; 0.13 (0.02, 6) 0.13 (0.02, 0.47) 0.12 (0.01, 0.79) N=2; 0.13 (0.09, 0.19) 0.14 (0.05, 0.36) N=2; 0.60 (0.08, 4.55) 0.42 (0.01, 9.00) 0.09 (0.001, 2.16) N=8; 0.67 (0.30, 1.50) 0.63 (0.26, 1.71) 0.08 (0.01, 0.37) 0.05 (7.69E-4, 1.56) 0.62 (0.10, 3.70) N=2; 0.65 (0.08, 5.26) 0 (0.24, 2.86) 0.65 (0.01, 16.67) 0.45 (0.01, 4.29) 0.69 (0.13, 4.00) efigure 5. Network Diagram of Randomized Controlled Trials Evaluating Overall Hypoglycemia (RR) With Noninsulin Antidiabetic Drugs in Addition to in Type 2 Diabetes Mellitus All agents are in combination with metformin. Solid lines represent the presence of direct evidence along with indirect evidence. Dotted lines represent the presence of indirect evidence only. Traditional pairwise meta-analysis results are reported as the top line in the format n=number of studies; relative risk (95%CI). Mixed-treatment comparison meta-analysis results, which combine both direct and indirect evidence are reported in the format relative risk (95%CrI). Arrows in the mixed-treatment comparison meta-analysis represent the favored drug and results reported are referent to the arrow origin. Thus, results may not correspond to numerical results reported elsewhere. Results referent to the second agent in a comparison equal 1/RR. Abbreviations: AGI=alpha-glucosidase inhibitor; DPP-4=dipeptidyl peptidase-4; GLP- 1=glucagon-like peptide-1; SU=sulfonylurea; TZD=thiazolidinediones
12 A. Change in A1c (%) B. A1c Goal Achieved (-7, -0.62) 2.49 (1.95, 3.32) (-7, -0.36) 2.25 (1.48, 3.90) (-8, -0.66) 2.71 (1.74, 3.80) (-3, -0.26) (-3, -0.64) No data 2.51 (2.04, 3.22) -7 (-1.30, -0.65) 3.20 (2.01, 6.24) Placebo (Referent) Placebo (Referent) Weighted Mean Difference (95% Credible Interval) Relative Risk (95% Credible Interval) C. Change in Body Weight (kg) D. Overall Hypoglycemia 2.06 (5, 2.96) 4.57 (2.11, 11.45) 1.77 (0.46, 3.28) 7.50 (2.12, 41.52) 2.08 (8, 3.17) 0.56 (0.19, 1.69) (-3.79, 0.21) 0.42 (0.01, 9.00) (-4, 0.63) 0.63 (0.26, 1.71) (-3.11, -0.48) 0.89 (0.22, 3.96) Placebo (Referent) Placebo (Referent) Weighted Mean Difference (95% Credible Interval) Relative Risk (95% Credible Interval) efigure 6. Results of Mixed Treatment Comparison Meta-analysis Presented as Forest Plots The squares represent the pooled effect size for each class of oral antidiabetic drug. Error bars represent 95% credible intervals (CrIs). The number of trials included in each mixed-treatment comparison analysis is as follows: A=26 trials, B=13 trials, C=15 trials, and D=24 trials. Abbreviations: AGI=alpha-glucosidase inhibitor; DPP-4=dipeptidyl peptidase-4; GLP- 1=glucagon-like peptide-1; SU=sulfonylurea; TZD=thiazolidinediones
Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis
Diabetes Ther (2018) 9:1995 2014 https://doi.org/10.1007/s13300-018-0493-2 ORIGINAL RESEARCH Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationCADTH Optimal use report
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Optimal use report Volume 3, Issue 1D July 2013 Optimal Use Recommendations
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationSupplementary Online Content
Supplementary Online Content Berkowitz SA, Krumme AA, Avorn J, et al. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. JAMA
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationScottish Medicines Consortium
Scottish Medicines Consortium saxagliptin, 5mg film-coated tablet (Onglyza ) No. (603/10) Bristol-Myers Squibb Pharmaceuticals Ltd 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationIpoglicemia: trattamento e strategie di prevenzione
Ipoglicemia: trattamento e strategie di prevenzione Antonio Ceriello Insititut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain Frequency of Hypoglycemia Increases as HbA1c Declines
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationPROCEEDINGS CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES * Vivian A. Fonseca, MD, FRCP ABSTRACT
CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES Vivian A. Fonseca, MD, FRCP ABSTRACT Despite proven lifestyle recommendations and the availability of a range of oral antidiabetic agents,
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationdapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca
dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 September 2012 (Issued 07 December 2012) The Scottish Medicines Consortium (SMC) has completed
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationCADTH THERAPEUTIC REVIEW New Drugs for Type 2 Diabetes: Second-Line Therapy Recommendations Report
CADTH THERAPEUTIC REVIEW New Drugs for Type 2 Diabetes: Second-Line Therapy Recommendations Report Product Line: Therapeutic Review Recommendations Volume: Volume 4 Issue: No. 1c Publication Date: May
More informationImpact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin
Diabetes Ther (2012) 3:8 DOI 10.1007/s13300-012-0008-5 ORIGINAL RESEARCH Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin Anja
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationNew Drugs for Type 2 Diabetes: Second-Line Therapy Recommendations Report
CADTH THERAPEUTIC REVIEW New Drugs for Type 2 Diabetes: Second-Line Therapy Recommendations Report Product Line: Volume: Issue: Publication Date: Report Length: Therapeutic Review Recommendations Disclaimer:
More informationSulfoniluree e glinidi: pro e contro
Sulfoniluree e glinidi: pro e contro Giorgio Sesti Università Magna Graecia di Catanzaro ITALY T2DM anti-hyperglycaemic therapy: general recommendations Diabetes Care 35:1364-1379, 2012; Diabetologia 55:1577-1596,
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationCADTH Optimal Use Report
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Optimal Use Report Volume 3, Issue 1B July 2013 Third-Line Pharmacotherapy for
More informationNew Drug Evaluation: lixisenatide injection, subcutaneous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationSYSTEMATIC REVIEW Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis
British Journal of Clinical Pharmacology Br J Clin Pharmacol (2016) 82 1291 1302 1291 SYSTEMATIC REVIEW Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis
More informationDiabetes Management DPP-4 Inhibitors
Dipeptidyl Peptidase-4 Inhibitors and the Management of Hyperglycemia Pamela M Katz, MD 1 and Lawrence A Leiter, MD 2 1. Resident, Division of Endocrinology and Metabolism, University of Toronto; 2. Head,
More informationSupplementary Online Content
Supplementary Online Content Geller AI, Shehab N, Lovegrove MC, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Internal
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACCORD (Action to Control Cardiovascular Disease and Diabestes), blood pressure goal, 74 ACEIs (Angiotensin-converting enzyme inhibitors),
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationComparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison
Diabetes Ther (2014) 5:1 41 DOI 10.1007/s13300-014-0061-3 REVIEW Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Paul
More informationCAMBRIDGESHIRE JOINT PRESCRIBING GROUP DECISION DOCUMENT Recommendation made by CJPG to Commissioners and Prescribers
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP DECISION DOCUMENT Recommendation made by CJPG to Commissioners and Prescribers Linagliptin (Trajenta, Boehringer Ingelheim Ltd) for the treatment of type 2 diabetes
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationEffective Health Care Program
Comparative Effectiveness Review Number 173 Effective Health Care Program Diabetes Medications for Adults With Type 2 Diabetes: An Update Executive Summary Condition and Therapeutic Strategies Type 2 diabetes
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationRESEARCH. Shanil Ebrahim, 7, 10, 12, 13 German Malaga, 14 Lorena P Rios, 15 Yingqiang Wang, 16 Qunfei Chen, 17 Gordon H Guyatt, 7, 18 Xin Sun 1
open access Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies Ling Li, 1 Sheyu Li, 2 Ke Deng, 3
More informationSitagliptin: A component of incretin based therapy. Rezvan Salehidoost, M.D., Endocrinologist
Sitagliptin: A component of incretin based therapy Rezvan Salehidoost, M.D., Endocrinologist Agenda Mode of Action Evidences for sitagliptine cardiovascular safety of sitagliptin Ramadan study Impact of
More informationEfficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Supplement issue Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD Diabetes and Metabolism Translational Medicine
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationIncretin Hormones: Evolving Treatment Strategies For Type 2 Diabetes
WHAT EVERY PRACTITIONER SHOULD KNOW ABOUT Incretin Hormones: Evolving Treatment Strategies For Type 2 Diabetes Education Partner: What Every Practitioner Should Know About Incretin Hormones: Evolving Treatment
More informationPhysiology of Normoglycemia
Case 1 45 year-old male patient seen at the clinic (Medicine). Workplace stress (financial analyst); occasionally goes jogging. Two-year duration of T2DM. No previous cardiovascular events. Coexisting
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationComparative Effectiveness and Safety of Diabetes Medications for Adults with Type 2 Diabetes
Draft Comparative Effectiveness Review Comparative Effectiveness and Safety of Diabetes Medications for Adults with Type Diabetes Prepared for: Agency for Healthcare Research and Quality U.S. Department
More informationAnti-diabetic Treatment in Obese Patients with Type 2 Diabetes Effects of Medication on Body Weight
Anti-diabetic Treatment in Obese Patients with Type 2 Diabetes Effects of Medication on Body Weight a report by Andrew J Krentz, MD, FRCP Consultant, Diabetes and Endocrinology, Southampton University
More informationCombination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
REVIEW Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential Nasser Mikhail Endocrinology Division, Olive View-UCLA Medical
More informationVolume : 05 Issue : 03 July-Sept Pages:
Middle East Journal of Applied Sciences Volume : 05 Issue : 03 July-Sept. 2015 Pages: 695-699 Efficacy and Safety of Vildagliptin as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Poorly Controlled
More informationMANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
More informationType 2 Diabetes Mellitus hypoglycaemic agents
Type 2 Diabetes Mellitus hypoglycaemic agents Name Metformin Drug Name (eg brand name) Metformin (Diaformin Diabex) Cost / PBS per 28d mth $10.24 (1.5g dly) 1000mg+500mg / $4.44+$5.80 Concerns? Lactic
More informationABSTRACT. at their Summary of Product Characteristics (SmPC) recommended daily doses, added on to metformin and SU. Comprehensive
Diabetes Ther (2017) 8:251 273 DOI 10.1007/s13300-017-0245-8 REVIEW Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic
More informationGlucagon-Like Peptide-1 (GLP-1) Agonists
Glucagon-Like Peptide-1 (GLP-1) Agonists Policy Number: 5.01.565 Last Review: 07/2018 Origination: 06/2014 Next Review: 07/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationType Two Diabetes Mellitus Prescribing in New Zealand - What are we dispensing?
Type Two Diabetes Mellitus Prescribing in New Zealand - What are we dispensing? Dr Bryan Betty Deputy Medical Director PHARMAC GP Cannons Creek, East Porirua Type 2 Diabetes in NZ: The Numbers 250,000
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationAhrén, Bo; Mathieu, Chantal; Bader, Giovanni; Schweizer, Anja; Foley, James E
Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Ahrén, Bo; Mathieu, Chantal; Bader, Giovanni; Schweizer,
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationNew Treatment Options for Type 2 Diabetes: Incretin-Based Therapy
New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy is supported by an educational grant from Novo Nordisk Inc. This program
More informationData from an epidemiologic analysis of
CLINICAL TRIAL RESULTS OF GLP-1 RELATED AGENTS: THE EARLY EVIDENCE Lawrence Blonde, MD, FACP, FACE ABSTRACT Although it is well known that lowering A 1c (also known as glycated hemoglobin) is associated
More informationUpdate on Agents for Type 2 Diabetes
Update on Agents for Type 2 Diabetes This presentation will: Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient-specific
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 December 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 December 2009 VICTOZA 6 mg/ml solution for injection in pre-filled pen Pack size of two 3 ml pens (CIP: 396 323-6)
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationEssential Medicines List (EML) 2017
Essential Medicines List (EML) 2017 Application for the revision of second line treatments of type II diabetes: considered agents that can be used in combination with metformin are sulfonylureas, meglitinides,
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationThe effective management of type 2
Approximately two thirds of patients with type 2 diabetes mellitus (T2DM) are unable to reach the hemoglobin A 1c target set by the American Diabetes Association ( 7.0%). Therefore, T2DM continues to be
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationUpdate on Agents for Type 2 Diabetes
Update on Agents for Type 2 Diabetes This presentation will: Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient-specific
More informationTypes of Diabetes that the Dipeptidyl Peptidase-4 Inhibitor May Act Effectively and Safely
The Open Diabetes Journal, 2011, 4, 1-5 1 Open Access Types of Diabetes that the Dipeptidyl Peptidase-4 Inhibitor May Act Effectively and Safely Hidekatsu Yanai * and Hiroki Adachi Department of Internal
More information(Incretin) ( glucagon-like peptide-1 GLP-1 ) GLP-1. GLP-1 ( dipeptidyl peptidase IV DPP IV ) GLP-1 DPP IV GLP-1 exenatide liraglutide FDA 2 2 2
007 18 189-194 (Incretin) Incretin ( ) -1 ( glucagon-like peptide-1 ) ( dipeptidyl peptidase IV ) liraglutide FDA ( Type diabetes mellitus ) -1 ( Glucagon-like peptide-1, ) ( Incretin ) ( Dipeptidyl peptidase
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationPatient Centric Treatment of Diabetes: The Role of GLP 1 Inhibitors
1:3 2:45pm Patient-Centric Treatment of Diabetes: The Role of GLP-1 Inhibitors SPEAKER Mark Molitch, MD Presenter Disclosure Information The following relationships exist related to this presentation:
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationUpdate on Pharmacological Management in Type 2 Diabetes
Update on Pharmacological Management in Type 2 Diabetes Prof. Lotfy Hamed Abo Dahab Professor Of Internal Medicine and Cardiology Vice President of Sohag University ١ My AGENDA Targets For Glycaemic Control
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationDr. Stanley Ho Medical Development Foundation Symposium Jan 2014 Advances in the Management of Type 2 Diabetes Mellitus
Dr. Stanley Ho Medical Development Foundation Symposium 2014 18 Jan 2014 Advances in the Management of Type 2 Diabetes Mellitus Dr Ronald Ma Professor Dept of Medicine & Therapeutics Prince of Wales Hospital
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationReview Article Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients
Journal of Diabetes Research Volume 2016, Article ID 6962574, 10 pages http://dx.doi.org/10.1155/2016/6962574 Review Article Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting
More informationA New Therapeutic Strategey for Type II Diabetes: Update 2008
Live, One Hour Webinar A New Therapeutic Strategey for Type II Diabetes: Update 2008 Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy in Grundy, Virginia.
More informationInformation for Patients
Information for Patients Guidance for Diabetic Persons having an OGD or Bronchoscopy This guidance is provided to assist with your preparation for your endoscopic procedure. If you feel unclear about how
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationDiabetic Management of the Cardiac Patient
Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:
More informationClinical Guidelines. Management of adult patients with diabetes undergoing endoscopic procedures
Clinical Guidelines Management of adult patients with diabetes undergoing endoscopic s Document Detail Document type Clinical Guideline Management of adult Patients with diabetes Undergoing Document name
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationOral Anti-diabetic Drugs in Older Adults with Diabetes
Oral Anti-diabetic Drugs in Older Adults with Diabetes Jae Min Lee Division of Endocrinology-Metabolism, Department of Internal Medicine, Eulji University Hospital, Eulji University School of Medicine,
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationThe design of the liraglutide clinical trial programme
review article Diabetes, Obesity and Metabolism 14 (Suppl. 2): 4 12, 2012. 2012 Blackwell Publishing Ltd The design of the liraglutide clinical trial programme M. A. Nauck Diabeteszentrum Bad Lauterberg,
More informationDiabetes Management Incretin Mimetics
The Incretin System and Type 2 Diabetes Anthony H Barnett, MD Professor of Medicine, Consultant Physician, and Clinical Director of Diabetes and Endocrinology, University of Birmingham and Heart of England
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationTargeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Richard E. Pratley and Matthew Gilbert
REVIEW Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors Richard E. Pratley and Matthew Gilbert Diabetes and Metabolism Translational Medicine Unit, University
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More information